ArticleBMC endocrine disorders2022
An association between adropin hormone and total testosterone in obese men: a case-control study.
Article in BMC endocrine disorders, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03724825 (Correlation of Serum Adropin to Testosterone and Adiponectin in Obese Men), which is not on this map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Correlation of Serum Adropin to Testosterone and Adiponectin in Obese Men
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.
- Risk factors for incidental prostate cancer following surgery for benign prostatic enlargement: A systematic review and meta-analysis.Prostate cancer and prostatic diseases · 2026Pooled it
- Adropin: A New Regulator of Testicular Function-What Do We Know So Far?International journal of molecular sciences · 2026Review
- Neuroendocrine effects of exogenous adropin administration on the hypothalamic pituitary testicular axis in male rats.Turkish journal of medical sciences · 2026Article
- The potential of ARL4C and its-mediated genes in atherosclerosis and agent development.Frontiers in pharmacology · 2025Review
- Serum adropin is unaltered in adolescents with histology-confirmed steatotic liver disease.Journal of pediatric gastroenterology and nutrition · 2025Article
- Association between serum testosterone changes and parameters of the metabolic syndrome.Endocrine journal · 2024Article
- Adropin: A crucial regulator of cardiovascular health and metabolic balance.Metabolism open · 2024Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundObesity is associated with low testosterone levels that could be caused by many mechanisms. Adropin, a peptide hormone, its levels are decreased in obesity and its receptors are expressed in the hypothalamus, the pituitary gland, and the testis. Adropin association to total testosterone in obese men is not detected yet. This study tries to find out possible associations between serum levels of adropin, adiponectin, total testosterone, and lipid profile in obese men.
methodsSerum levels of adropin, adiponectin, total testosterone, and lipid profile parameters were measured in 43 obese men and 40 age-matched normal-weight men.
resultsAdropin, adiponectin, and testosterone levels were significantly lower in obese men versus normal-weight men. In all participants, positive correlations between adropin, adiponectin, and total testosterone were detected. Adropin is considered a predictor risk factor for testosterone.
conclusionsThis study suggests a possible causal relationship between adropin and total testosterone which needs further investigation.
trial registrationClincialtrials.gov NCT03724825 , registered October 30th, 2018.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.